According to the US Centers for Disease Control and Prevention, substance use disorder (SUD) affects approximately one in six ...

Schrödinger said it is ending development of the CHC7 inhibitor in blood cancer as both a monotherapy and combination.

Remegen's Telitacicept met its primary endpoints in a Chinese trial, while a US-based Phase III trial in Sjögren's syndrome ...

Vendanta's CEO also announced the company is cutting 20% of its workforce as a result of the Phase II UC trial failure.